Calliditas Therapeutics AB American Depositary Shares
CALT
CALT was delisted on the 20th of September, 2024.
13 hedge funds and large institutions have $19.7M invested in Calliditas Therapeutics AB American Depositary Shares in 2021 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 4 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
0.76% less ownership
Funds ownership: 4.25% → 3.49% (-0.76%)
7% less funds holding
Funds holding: 14 → 13 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
89% less capital inflows, than outflows
Capital inflows: $759K | Capital outflows: $6.63M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$373K |
| 2 |
Ironwood Investment Management
Boston,
Massachusetts
|
+$328K |
| 3 |
Morgan Stanley
New York
|
+$27.2K |
| 4 |
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
+$17.1K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$5.29K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$4.25M |
| 2 |
Vivo Capital
Palo Alto,
California
|
-$1.84M |
| 3 |
Jane Street
New York
|
-$211K |
| 4 |
Next Financial Group
Houston,
Texas
|
-$122K |
| 5 |
Pentwater Capital Management
Naples,
Florida
|
-$110K |
CALT Hedge Fund Activity: Q3 2021 in Review
13 of the 5,731 institutional investors tracked by Wall St. Rank reported a position in Calliditas Therapeutics AB American Depositary Shares (CALT) for Q3 2021, worth a combined $19.7M — down 40% from $32.7M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of CALT and 3 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 5 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $373K. The largest seller was Endurant Capital Management, exiting entirely with an estimated $4.25M sold.
- 13 institutional investors held Calliditas Therapeutics AB American Depositary Shares (CALT) as of Q3 2021, down from 14 in Q2 2021.
- Funds reported $19.7M of Calliditas Therapeutics AB American Depositary Shares stock for Q3 2021, down 40% quarter-over-quarter.
- 3 funds opened new Calliditas Therapeutics AB American Depositary Shares positions in Q3 2021 and 4 closed out, a net change of -1 holder.
- The largest Calliditas Therapeutics AB American Depositary Shares buyer in Q3 2021 was Renaissance Technologies, an estimated $373K added.
- The largest Calliditas Therapeutics AB American Depositary Shares seller in Q3 2021 was Endurant Capital Management, an estimated $4.25M sold.
Based on aggregated 13F filings for Q3 2021.